Oligometastases in prostate cancer: Ablative treatment.

ABSTRACT: Technological advances in radiotherapy have led to the introduction of techniques such as stereotactic body radiation therapy (SBRT), allowing the administration of ablative doses. The hypothesis that oligometastatic disease may be cured through local eradication therapies has led to the increasing use of SBRT in patients with this type of disease. At the same time, scientific advances are being made to allow the confirmation of clinically suspected oligometastatic status at molecular level. There is growing interest in identifying patients with oligometastatic prostate cancer (PCa) who may benefit from curative intent metastasis-directed therapy, including SBRT. The aim is to complement, replace or delay the introduction of hormone therapy or other systemic therapies. The present review a

SUBMITTER: Palacios-Eito A 

PROVIDER: S-EPMC6390116 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature